Skip to main content

Table 1 Clinicopathological parameters in patients with breast cancer

From: Loss of histone H4K20 trimethylation predicts poor prognosis in breast cancer and is associated with invasive activity

  

H3K9me3

   

H4K20me3

 
 

score

0

1+

2+

  

score

0

1+

2+

 
 

N = 71

25

22

24

  

N = 93

36

23

34

 
  

35.2

31.0

33.8

(%)

  

38.7

24.7

36.6

(%)

 

N

   

P*

 

N

   

P*

Pathological classification

71

   

0.503

Pathological classification

93

   

0.478

DCIS, microinvasive

 

1

5

3

 

DCIS, microinvasive

 

1

3

4

 

idc, pap

 

9

9

7

 

idc, pap

 

11

8

10

 

idc, sol

 

4

3

3

 

idc, sol

 

10

3

3

 

idc, sci

 

8

2

6

 

idc, sci

 

8

4

10

 

special type

 

3

3

5

 

special type

 

6

5

7

 

Lymph node metastasis

64

   

0.493

Lymph node metastasis

83

   

0.060

0-3

 

20

15

16

 

0-3

 

22

19

25

 

3<

 

3

4

6

 

3<

 

11

3

3

 

Nuclear grade

70

   

0.838

Nuclear grade

91

   

0.022

1

 

12

12

9

 

1

 

8

10

21

 

2

 

4

4

4

 

2

 

7

4

6

 

3

 

9

6

10

 

3

 

19

9

7

 

ER

70

   

0.707

ER

93

   

0.027

Negative

 

9

9

11

 

Negative

 

21

10

9

 

Positive

 

16

13

12

 

Positive

 

15

13

25

 

PgR

68

   

0.590

PgR

91

   

0.019

Negative

 

10

9

12

 

Negative

 

21

13

10

 

Positive

 

14

13

10

 

Positive

 

13

10

24

 

HER2

71

   

0.580

HER2

93

   

0.082

Negative (0/1)

 

20

15

19

 

Negative (0/1)

 

29

14

29

 

Positive (2/3)

 

5

7

5

 

Positive (2/3)

 

7

9

5

 

Intrinsic subtype

69

   

0.462

Intrinsic subtype

91

   

0.002

Luminal

 

18

14

12

 

Luminal

 

14

14

28

 

Non-luminal

 

7

8

10

 

Non-luminal

 

20

9

6

 

MIB-1 index

69

   

0.482

MIB-1 index

91

   

0.001

<30

 

14

9

9

 

<30

 

9

8

24

 

30≦

 

11

13

13

 

30≦

 

25

15

10

 
  1. *Chi-squared test. Bold indicates values that are statistically significant. DCIS, ductal carcinoma in situ; idc, invasive ductal carcinoma; pap, papillotubular carcinoma; sol, solid-tubular carcinoma; sci, scirrhous carcinoma; ER, estrogen receptor; PgR, progesterone receptor; luminal, ER positive and/or PgR positive.